223 related articles for article (PubMed ID: 9578576)
21. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E
J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853
[TBL] [Abstract][Full Text] [Related]
22. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
23. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323
[TBL] [Abstract][Full Text] [Related]
24. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
[TBL] [Abstract][Full Text] [Related]
25. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
26. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
27. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
31. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
[TBL] [Abstract][Full Text] [Related]
33. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.
Souness JE; Scott LC
Biochem J; 1993 Apr; 291 ( Pt 2)(Pt 2):389-95. PubMed ID: 8387267
[TBL] [Abstract][Full Text] [Related]
34. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
35. The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task.
Giorgi M; Modica A; Pompili A; Pacitti C; Gasbarri A
Behav Brain Res; 2004 Sep; 154(1):99-106. PubMed ID: 15302115
[TBL] [Abstract][Full Text] [Related]
36. Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast.
McHale MM; Cieslinski LB; Eng WK; Johnson RK; Torphy TJ; Livi GP
Mol Pharmacol; 1991 Feb; 39(2):109-13. PubMed ID: 1847489
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
Sawanishi H; Suzuki H; Yamamoto S; Waki Y; Kasugai S; Ohya K; Suzuki N; Miyamoto K; Takagi K
J Med Chem; 1997 Sep; 40(20):3248-53. PubMed ID: 9379444
[TBL] [Abstract][Full Text] [Related]
38. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram.
Shakur Y; Pryde JG; Houslay MD
Biochem J; 1993 Jun; 292 ( Pt 3)(Pt 3):677-86. PubMed ID: 7686364
[TBL] [Abstract][Full Text] [Related]
39. The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Gordeladze JO
Biosci Rep; 1990 Aug; 10(4):375-88. PubMed ID: 2174276
[TBL] [Abstract][Full Text] [Related]
40. Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells.
Xiong Y; Westhead EW; Slakey LL
Biochem J; 1995 Jan; 305 ( Pt 2)(Pt 2):627-33. PubMed ID: 7832782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
